Araştırma Makalesi

Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris

Cilt: 9 Sayı: 34 1 Eylül 2018
PDF İndir
TR EN

Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris

Öz

Objectives:Isotretinoin (ISO) is a synthetic analog of vitamin A used at the doses of 0.5–2 mg/kg for four to five months in the treatment of moderate to severe acne vulgaris. In the present study, both hematological and inflammatory parameters were retrospectively assessed in patients receiving ISO therapy for acne vulgaris.

Method: This study included 352 patients who were admitted to the Dermatology Clinic and received oral ISO for the treatment of acne vulgaris were included in the study. Each patient’s hematological and inflammatory parameters (hemoglobin, hematocrit, thrombocyte, mean platelet volume, leukocyte, erythrocyte, neutrophil, lymphocyte, monocyte, eosinophil, basophil, neutrophil/basophil, thrombocyte/lymphocyte, RDW, PCT and PDW) were evaluated before the treatment and retrospectively evaluated four months after the onset of treatment. 

Results: After treatment, a significant decrease was detected in the levels of leukocyte, neutrophil and neutrophil to lymphocyte ratio (NLR) (an indicator of inflammation), and a significant increase was detected in the levels of thrombocyte and procalcitonin (PCT).

Conclusion: In our study, isotretinoin inhibited the anti-inflammatory effect of isotretinoin treatment of acne in patients with NLR decline after treatment with inflammatory markers. Patients with markedly elevated platelet counts or low leukocyte counts should be closely monitored.

Anahtar Kelimeler

Kaynakça

  1. Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges.2007;5:316-23.
  2. Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet 1980; 2: 1048–9.
  3. Boyraz N, Mustak PK. Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimensin the treatment of moderate acne vulgaris. Int J Dermatol.2013;52:1265-7.
  4. Michaëlsson G, Vahlquist A, Mobacken H, Hersle K, Landegren J, Rönnerfält L, et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol 1986; 66: 144–8.
  5. Moeller KE, Touma SC. Prolonged thrombocytopenia associated with isotretinoin. AnnPharmacother 2003;37:1622–4.
  6. Friedman SJ. Leukopenia and neutropeniaassociated with isotretinoin therapy. Arch Dermatol 1987; 123: 293-5.
  7. Jansen T, Altmeyer P. Thrombocytosis induced by low-doseisotretinoin. Int J Dermatol 2000; 39: 956-7.
  8. Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol 2014; 33: 223-7.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Reyhan Çetinkaya Bu kişi benim
Türkiye

Berna Solak Bu kişi benim
Türkiye

Yayımlanma Tarihi

1 Eylül 2018

Gönderilme Tarihi

6 Mayıs 2018

Kabul Tarihi

14 Aralık 2018

Yayımlandığı Sayı

Yıl 2018 Cilt: 9 Sayı: 34

Kaynak Göster

APA
Yaldız, M., Çetinkaya, R., & Solak, B. (2018). Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris. The Medical Journal of Mustafa Kemal University, 9(34), 61-67. https://doi.org/10.17944/mkutfd.421437
AMA
1.Yaldız M, Çetinkaya R, Solak B. Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris. mkutfd. 2018;9(34):61-67. doi:10.17944/mkutfd.421437
Chicago
Yaldız, Mahizer, Reyhan Çetinkaya, ve Berna Solak. 2018. “Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris”. The Medical Journal of Mustafa Kemal University 9 (34): 61-67. https://doi.org/10.17944/mkutfd.421437.
EndNote
Yaldız M, Çetinkaya R, Solak B (01 Eylül 2018) Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris. The Medical Journal of Mustafa Kemal University 9 34 61–67.
IEEE
[1]M. Yaldız, R. Çetinkaya, ve B. Solak, “Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris”, mkutfd, c. 9, sy 34, ss. 61–67, Eyl. 2018, doi: 10.17944/mkutfd.421437.
ISNAD
Yaldız, Mahizer - Çetinkaya, Reyhan - Solak, Berna. “Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris”. The Medical Journal of Mustafa Kemal University 9/34 (01 Eylül 2018): 61-67. https://doi.org/10.17944/mkutfd.421437.
JAMA
1.Yaldız M, Çetinkaya R, Solak B. Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris. mkutfd. 2018;9:61–67.
MLA
Yaldız, Mahizer, vd. “Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris”. The Medical Journal of Mustafa Kemal University, c. 9, sy 34, Eylül 2018, ss. 61-67, doi:10.17944/mkutfd.421437.
Vancouver
1.Mahizer Yaldız, Reyhan Çetinkaya, Berna Solak. Assessment of Hematological and Inflammatory Parameters in Patients Receiving Isotretinoin Therapy for Acne Vulgaris. mkutfd. 01 Eylül 2018;9(34):61-7. doi:10.17944/mkutfd.421437

Cited By